Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as radioligand [18F]AZD4694
radioligand AZD4694 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| radioligand [18F]AZD4694 | DRUG | single dose of iv. admin. 1-2 times per subject |
| radioligand [11C]AZD2184 | DRUG | single dose of iv admin. 1 time per subject |
Inclusion Criteria: * Alzheimer's Disease patients - 50-85 years, mild to moderate AD: MMSE ≥16 and ≤ 26, clinical progression of AD over 12 months. * Healthy volunteers: - 50-75 years * BMI 18 and 30 m2/kg * Clinically normal physical findings including supine blood pressure and pulse rate. Exclu...
Top 20 of 30 competitors
Radioligand AZD4694, also written as radioligand [18F]AZD4694, is an investigational small molecule PET imaging agent developed by AstraZeneca PLC (ticker AZN). It is being studied in Alzheimer's disease as a candidate positron emission tomography ligand for brain amyloid beta, the protein deposits associated with the disease.
Radioligand AZD4694 is used as a positron emission tomography imaging agent to detect amyloid beta in the brain in people being evaluated for Alzheimer's disease. In its Phase 1 study it was compared with [11C]AZD2184, another candidate PET ligand for amyloid beta, in participants aged 50 years and older.
Radioligand AZD4694 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 1 PET imaging study of the compound conducted in Sweden.
Radioligand AZD4694 is in Phase 1 clinical development and is investigational. It has completed one Phase 1 trial, and no active trials of the compound are currently listed.
Radioligand AZD4694 has been studied in one completed Phase 1 trial, NCT00838877, titled "Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Abeta Amyloid." The study enrolled 26 participants in Sweden, including healthy volunteers, and was an uncontrolled, non-randomized design.
Yes. Radioligand AZD4694 and radioligand [18F]AZD4694 refer to the same AstraZeneca compound. The bracketed form specifies the fluorine-18 radioisotope used in the molecule, which is the labeling form described in the Phase 1 PET imaging trial NCT00838877.